What is a liquid biopsy?

A liquid biopsy is a blood test that looks for cancer cells, or pieces of tumor DNA, that a tumor has shed into the blood.

The name is a little misleading, because nothing is cut. Tumors constantly shed cells and bits of material into the bloodstream. A liquid biopsy takes a tube of blood and hunts for that debris. Tests that look at tumor markers in blood and other body fluids are the reason the term exists.

Some tumor markers can be found in those blood-borne tumor fragments. Genomic markers, such as tumor gene mutations, are among them. So a liquid biopsy is one way to measure the molecular traits of a cancer without taking a tissue sample. Some of these results may appear in reports linked to a pathology report.

The clearest reason to use one is access. NCI describes a liquid biopsy as an option when a tumor biopsy cannot be done safely. A tumor that is hard to reach with a needle is the usual example. A blood draw also takes minutes rather than a procedure slot, and it can be repeated as often as needed. That helps when doctors want to watch a cancer change over months, not just take one snapshot.

What comes back can be genuinely useful. Genomic markers include tumor gene mutations, patterns of tumor gene expression, and nongenetic changes in tumor DNA. A result may show your cancer carries a biomarker matched to a known therapy. That could be an approved drug, an off-label option, or a clinical trial. Some tests measure tumor mutational burden, which helps predict whether immune checkpoint inhibitors are worth trying. Tumor marker results also help estimate prognosis, track whether treatment is working, and watch for a cancer coming back.

The limits matter just as much, and they are easy to miss.

A liquid biopsy sees only what is circulating on the day of the draw. Not all of your cancer cells carry the same biomarkers. A test can therefore miss a mutation that is present in the tumor itself. That is why a negative liquid biopsy often does not close the question. A tissue sample may still be needed.

An abnormal result does not automatically mean cancer either. Noncancerous conditions can raise tumor marker levels.

These tests are also not screening tools. NCI states that studies generally found tumor markers do not work well for screening. They are neither sensitive enough nor specific enough. Multi-cancer detection tests look at many blood biomarkers at once. They are being studied, but they remain research.

A liquid biopsy is one tool among several, and results are used together with other tests. Your healthcare team is the best source of information about whether a liquid biopsy is useful in your situation. Three questions make the answer concrete. Would the result change what we do next? If it comes back negative, do I still need a tissue biopsy? And is this test standard care for my cancer, or part of a study?